Volume : 2, Issue : 8, AUG 2016

INFLUENCE OF CLINICAL PATHOLOGICAL CHARACTERISTICS OF ADENOCARCINOMA OF THE STOMACH ON SURVIVAL TIME OF PATIENTS POST-SURGERY

Indira Mehmedagi?, Šefik Hasuki?, Nedžad Kadri?

Abstract

Aim: The aim of this study was to determine the influence of specific prognostic factors on the survival time of patients who have been operated on in Tuzla Canton in Bosnia and Herzegovina.
Method: Retrospective - prospective five-year study that was performed in University Clinical Center in Tuzla, the Department of Surgery, included 100 patients treated from adenocarcinoma in the period 01.01.2010 - 31.12.2015. Data about type of gastric resection, lymphadenectomy and splenectomy, were obtained from operational note and formed a first group of prognostic factors. The second group included pathological characteristics of the tumor, including size, location, its histological type, Borrmann's classification, differentiation, characteristics of resection lines, number of metastatic lymph nodes, peritoneal dissemination, and distance metastases. Data obtained from the Institute of Pathology, University Clinical Center in Tuzla.
Results: Tumors located in the antrum (p<0.0446) were the most valuable for prognoses. Subtotal gastrectomy had the best statistical value (p< 0.036). In 79% cases where splenectomy was not performed, the survival time was longer making splenectomy a significant prognostic factor (p<0.0013).
Conclusion: Factors that influenced survival time, as a measure of relative risk, include tumor size, its location, the TNM stage, and the type of operation. A longer survival time 12 - 15 months was present where subtotal gastrectomy was performed without splenectomy on patients with a tumor in the antrum. With tumor < 5 cm, at stage T3 and T4, and where other types of operations were performed, the average survival time was 7 - 8 months.

Article : Download PDF

Cite This Article

Article No : 7

Number of Downloads : 933

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin.
2016;66(1):7.
2. Markar SR, Karthikesalingam A, Jackson D, Hanna GB. Long-term survival after
gastrectomy for cancer in randomized, controlled oncological trials: comparison
between West and East. Ann SurgOncol. 2013 Jul;20(7):2328-38.
3. Cabebe E, Mehta V, Fisher G. Gastric Cancer. eMedicine Specialties > Oncology > Carcinomas
of the Gastrointestinal Tract. 2009
4. Songun I, Velde C, Arends J, Blok P, Grond J, Offerhaus J, Hermans J, Krieken J. Classification
of gastric carcinoma using the Goseki system provides prognostic information
additional to TNM staging. Cancer.2000; 85 (10): 2114-2118.
5. Anonymous (2008 a) About Gastric Cancer (Biomarkers) Knovledgebase (datebase on
the Internet) (updated 2008-April-27). Available from: htpp://biomarkers.bii.astar.
edu.sg/background/gastricCancerBiomarkersKb.php.
6. Adachi Y, Kitano S, Sugimachi K. Surgery for gastric cancer: 10-year experience
worldwide. Gastric Cancer. 2001; 4 (4): 166-74.
7. Jaehne J, Meyer HJ, Maschec H, Geerlings H, Burns E, Pichlmayr R
Lymphadenectomi in gastric carcinoma. A prospective and prognostic study. Ann
SurgOncolo. 2002; 9: 775-784.
8. Hasuki? Š, Muratovi? O, Hasuki? I. Use of a circular stapler for Billroth I anastomosis
after distal gastrectomy. South African Journal Of Surgery 2013; 51(4), 144-145.
doi:10.7196/sajs.1631.
9. Isg?der AS, Nazli O, Tansug T, Bozdag AD, Onal MA. Total gastrectomy for gastric carcinoma.
Hepatogastroenterology .2005; 52 (61): 302-304.
10. Gorbunov EA, Wechsler J, Stašek T, Tomin AS, Solodun I.D. Significant prognostic factors
in 283 patients after surgery for adenocarcinoma of the stomach. Scriptamedica
(Brno) 2005; 78 (1): 3-16.
11. Datta J, Lewis RS Jr, Mamtani R, Stripp D, Kelz RR, Drebin JA, Fraker DL, Karakousis
GC, Roses RE. Implications of inadequate lymph node staging in resectable gastric cancer:
a contemporary analysis using the National Cancer Data Base. Cancer.
2014;120(18):2855.
12. Costa MLV, Ribeiro KCB, Machado MAC, Costa ACLV, Montagnini AL. Prognostic
Score in Gastric Cancer: The Importance of a Conjoint Analysis of Clinical, Pathologic,
and Therapeutic Factors. Annals of Surgical Oncology.2006; 13 (6): 843-850.
13. Yokota T, Ishiyama S, Saito T, Teshima S, Yamada Y, Iwamoto K, Takahashi M, Murata
K, Yamauchi H. Is tumor size a prognostic indicator for gastric carcinoma. Anticancer
Res. 2002; 22 (6B): 3673-3677.
14. Oh CA, Bae JM, Oh SJ, Choi MG, Noh JH, Sohn TS, Kim S . Long-term results and
prognostic factors of gastric cancer patients with only positive peritoneal lavage cytology.
J SurgOncol. 2012 Mar;105(4):393-9. Epub 2011 Sep 6.
15. Kim DY, Joo JK, Park YK, Ryu SY, Kim YJ, Kim SK. Prognostic Factors in Gastric Carcinoma
with Peritoneal Dissemination. ActaChirBelg 2006; 106, 665-668.
16. Hansson LE, Ekström AM, BergströmDScR, Nyrén O. Carcinoma of the gastridc
cardia: surgical practices and short-term operative results in a defined Swedish population.
World J Surg. 2000; 24 (4): 473-478.
17. Mocellin S, McCulloch P, Kazi H, Gama-Rodrigues JJ, Yuan Y, Nitti D. Extent of
lymph node dissection for adenocarcinoma of the stomach. Cochrane Database Syst
Rev. 2015;8:CD001964.
18. Dikken JL, Baser RE, Gonen M, Kattan MW, Shah MA, Verheij M, van de Velde CJ,
Brennan MF, Coit DG. Conditional probability of survival nomogram for 1-, 2-, and 3-
year survivors after an R0 resection for gastric cancer. Ann SurgOncol.
2013;20(5):1623.
19. 19Ruiz E, Sanchez J, Celis J, Payet E, Berrospi F, Chavez I, Young F. Surgical outcome
of 801 patients with localized gastric cancer treated with D2 lymphadenectomy. Rev
Gastroenterol Peru. 2009; 29 (2): 124-131.
20. El-Sedfy A, Dixon M, Seevaratnam R, Bocicariu A, Cardoso R, Mahar A, Kiss A,
Helyer L, Law C, Coburn NG Personalized Surgery for Gastric Adenocarcinoma: A
Meta-analysis of D1 versus D2 Lymphadenectomy. Ann SurgOncol. 2015
Jun;22(6):1820-7. Epub 2014 Oct 28.
21. Lorenz M, Roukos D, Hottenrott C, Ence A. Preservation vs Resection of the Spleen for
Gastric Cancer. Gastric Breast Cancer.2002; 1 (2): 31-38.
22. Bria E, De Manzoni G, Beghelli S, Tomezzoli A, Barbi S, Di Gregorio C, Scardoni M,
Amato E, Frizziero M, Sperduti I, Corbo V, Brunelli M, Bersani S, Tortora G, Scarpa A.
A clinical-biological risk stratification model for resected gastric cancer: prognostic
impact of Her2, Fhit, and APC expression status. Ann Oncol. 2013 Mar;24(3):693-701.
Epub 2012 Nov 6.